Sort   by:  
 Page size 
UnknownEfficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Not available
S-EPMC7447657 | biostudies-literature
UnknownEfficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Not available
S-EPMC7720359 | biostudies-literature
Sort   by:  
 Page size